Research and pilot analysis of bevacizumab repurposing potential and its impact in clinical practice
Repurposing of drugs is a strategy for discovering new uses for already authorized or tested medicines outside their original indications. Bevacizumab is humanized antibody, observed to have anti-VEGF (Vascular Endothelial Growth Factor) effect, which is indicated for colorectal, lung and other type...
Saved in:
| Main Authors: | Antonio Ivanov, Violeta Getova-Kolarova, Valentina Belcheva, Evgeni Grigorov, Ilko Getov |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Biotechnology & Biotechnological Equipment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/13102818.2024.2357191 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety and tolerability of a bevacizumab biosimilar (Effivia®) in adult Mexican patients with cancer: a multicenter, observational, prospective clinical study
by: Alberto Alfonso Pimentel-Rentería, et al.
Published: (2025-05-01) -
Real-World Evidence for Comparative Outcomes between Innovator and Biosimilar Bevacizumab in Advanced Colorectal Cancers
by: Arvind Vaidyanathan, et al.
Published: (2024-10-01) -
Efficacy and safety of bevacizumab biosimilar SIBP04 compared with bevacizumab (Avastin®) as first-line treatment for locally advanced or metastatic non-squamous non-small-cell lung cancer: A randomized, double-blind, phase 3 trial
by: Yuankai Shi, et al.
Published: (2025-07-01) -
Atezolizumab and Bevacizumab in Therapy for Patients with Hepatocellular Carcinoma in Real Clinical Practice
by: G. A. Serebrennikov, et al.
Published: (2023-07-01) -
Long-term results of a randomized controlled trial of biosimilar CT-P16 and reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer
by: Zoran Andric, et al.
Published: (2025-01-01)